Efficacy of trastuzumab combined with neratinib in the treatment of HER-2 positive metastatic breast cancer
- VernacularTitle:曲妥珠单抗联合奈拉替尼治疗HER-2阳性转移性乳腺癌的疗效
- Author:
Wei WANG
1
;
Haishui XIA
;
Shang MA
Author Information
- Publication Type:Journal Article
- Keywords: breast neoplasms; receptor,ErbB-2; Trastuzumab; Neratinib; human epidermal growth factor receptor-2 positive metastatic breast cancer
- From: Tianjin Medical Journal 2025;53(3):321-325
- CountryChina
- Language:Chinese
- Abstract: Objective To investigate the efficacy of trastuzumab combined with neratinib on human epidermal growth factor receptor(HER)-2 positive metastatic breast cancer and its impact in the immune function and quality of life of patients.Methods Eighty-two patients with HER-2 positive metastatic breast cancer admitted to our hospital(from June 2022 to December 2023)were included and used as research objects.Patients were separated into the neratinib group and the combination group stochastically,with 41 cases in each group.The neratinib group was treated with neratinib maleate,and the combined group was treated with trastuzumab for injection on the basis of neratinib group for 6 courses of treatment.The clinical efficacy,quality of life scores(FACT-B),immune function indicators(CD4+,CD8+,CD4+/CD8+),tumor marker indicators[carbohydrate antigen(CA)125,CA153,carcinoembryonic antigen(CEA)]and adverse reactions were observed before treatment and after 6 courses of treatment between two groups.Results The overall clinical symptom relief rate was greatly higher in the combination group than that of the neratinib group(P＜0.05).Before treatment,there were no significant differences in quality of life,immune function and tumor markers between the two groups(P＞0.05).After treatment,FACT-B score,CD4+,CD4+/CD8+levels were higher in the two groups than before treatment(P＜0.05),while CD8+,CA125,CA153 and CEA levels were lower than before treatment(P＜0.05),and changes of indexes were more significant in the combination group than those in the nilatinib group(P＜0.05).During treatment,the incidence of adverse reactions was lower in the combination group than that in the nilatinib group(P＜0.05).Conclusion Trastuzumab combined with neratinib is effective and safe in the treatment of HER-2 positive metastatic breast cancer.
